Clinical Trial Update: Safety and Efficacy of BKM120 in Relapsed and Refractory NHL [Phase 2]

View source ↗

Summary

Phase 2 trial updating safety and efficacy of BKM120 in relapsed/refractory non-Hodgkin lymphomas (diffuse large B-cell, mantle cell, and follicular).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• BKM120 (Buparlisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-09-28